Menu
Search
|

Menu

Close
X

Opiant Pharmaceuticals Inc OPNT.OQ (NASDAQ Stock Exchange Capital Market)

25.39 USD
-1.11 (-4.19%)
As of Feb 17
chart
Previous Close 26.50
Open 26.65
Volume 4,436
3m Avg Volume 12,729
Today’s High 26.65
Today’s Low 25.05
52 Week High 51.90
52 Week Low 17.01
Shares Outstanding (mil) 2.03
Market Capitalization (mil) 72.86
Forward P/E 14.34
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
18
FY16
10
FY15
2
EPS (USD)
FY18
-2.772
FY17
2.887
FY16
-4.875
FY15
-3.870
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
14.34
32.90
Price to Sales (TTM)
vs sector
4.86
5.77
Price to Book (MRQ)
vs sector
16.95
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
231.11
14.43
Return on Equity (TTM)
vs sector
2,031.09
16.13

EXECUTIVE LEADERSHIP

Michael Sinclair
Executive Chairman of the Board, Since 2012
Salary: $314,583.00
Bonus: $10,000.00
Roger Crystal
President, Chief Executive Officer, Director, Since 2009
Salary: $402,083.00
Bonus: $50,000.00
David O'Toole
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Arvind Agrawal
Executive Vice President - Medical Affairs, Since 2015
Salary: --
Bonus: --
Phil Skolnick
Chief Scientific Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

201 Santa Monica Blvd Ste 500
SANTA MONICA   CA   90401-2213

Phone: +1310.5985410

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

SPONSORED STORIES